Excelsior Medical Co., Ltd. (TPE:4104)
87.20
+3.60 (4.31%)
Apr 10, 2025, 1:35 PM CST
Excelsior Medical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 771.26 | 746.61 | 667.45 | 607.15 | 571.67 | Upgrade
|
Depreciation & Amortization | 297.88 | 263.64 | 220.6 | 200.82 | 164.81 | Upgrade
|
Other Amortization | 2.95 | 2.04 | 1.84 | 2.14 | 2.66 | Upgrade
|
Loss (Gain) From Sale of Assets | -0.76 | -20.42 | -0.17 | -0.01 | 0.1 | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | 2.18 | - | 4.28 | Upgrade
|
Loss (Gain) From Sale of Investments | -1.86 | 0.69 | 1.72 | 6.64 | 0.2 | Upgrade
|
Loss (Gain) on Equity Investments | -323.19 | -342.3 | -290.24 | -233.43 | -242.03 | Upgrade
|
Stock-Based Compensation | - | - | - | - | 4.15 | Upgrade
|
Provision & Write-off of Bad Debts | 0.49 | -0.9 | 13.22 | 7.05 | 2.91 | Upgrade
|
Other Operating Activities | 180.32 | 245.82 | 172.32 | 150.8 | 147.77 | Upgrade
|
Change in Accounts Receivable | -68.84 | -241.44 | -62.83 | -138.48 | 65.03 | Upgrade
|
Change in Inventory | -264.07 | -139.99 | -312.96 | -121.87 | -36.47 | Upgrade
|
Change in Accounts Payable | 4.11 | -27.92 | 52.86 | 65.26 | -171.24 | Upgrade
|
Change in Unearned Revenue | -15.57 | 74.23 | 105.72 | 67.25 | -8.58 | Upgrade
|
Change in Other Net Operating Assets | 1,889 | -452.94 | 65.43 | 331.73 | 364.18 | Upgrade
|
Operating Cash Flow | 2,471 | 107.1 | 637.13 | 945.05 | 869.43 | Upgrade
|
Operating Cash Flow Growth | 2207.58% | -83.19% | -32.58% | 8.70% | -27.21% | Upgrade
|
Capital Expenditures | -114.87 | -126.37 | -171.6 | -164.69 | -30.72 | Upgrade
|
Sale of Property, Plant & Equipment | 1.03 | 36.46 | 2.6 | 0.09 | 0.29 | Upgrade
|
Cash Acquisitions | - | -3.86 | - | - | - | Upgrade
|
Divestitures | - | - | 2.76 | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -5.83 | -16.27 | -0.85 | -4.06 | -4.32 | Upgrade
|
Investment in Securities | -46.4 | 34.8 | -740.12 | 256.11 | -355.62 | Upgrade
|
Other Investing Activities | 349.66 | 180.98 | 313.86 | 77.76 | 185.4 | Upgrade
|
Investing Cash Flow | -65.57 | 105.75 | -690.01 | 144.13 | -414.85 | Upgrade
|
Short-Term Debt Issued | - | 599.75 | 55.17 | 75.47 | - | Upgrade
|
Total Debt Issued | - | 599.75 | 55.17 | 75.47 | - | Upgrade
|
Short-Term Debt Repaid | -217.36 | - | - | - | -808.47 | Upgrade
|
Long-Term Debt Repaid | -101.27 | -97.7 | -82.58 | -79.69 | -80.05 | Upgrade
|
Total Debt Repaid | -318.63 | -97.7 | -82.58 | -79.69 | -888.52 | Upgrade
|
Net Debt Issued (Repaid) | -318.63 | 502.05 | -27.41 | -4.22 | -888.52 | Upgrade
|
Issuance of Common Stock | - | - | - | - | 585 | Upgrade
|
Common Dividends Paid | -591.34 | -540.95 | -494.02 | -494.02 | -465.79 | Upgrade
|
Other Financing Activities | -45.99 | -65.61 | -112.46 | -95.67 | 166.02 | Upgrade
|
Financing Cash Flow | -955.96 | -104.51 | -633.89 | -593.91 | -603.28 | Upgrade
|
Foreign Exchange Rate Adjustments | 124.5 | -0.54 | 121.5 | -41.47 | -61.61 | Upgrade
|
Net Cash Flow | 1,574 | 107.79 | -565.27 | 453.8 | -210.31 | Upgrade
|
Free Cash Flow | 2,357 | -19.27 | 465.53 | 780.36 | 838.72 | Upgrade
|
Free Cash Flow Growth | - | - | -40.34% | -6.96% | -26.64% | Upgrade
|
Free Cash Flow Margin | 27.60% | -0.23% | 6.48% | 11.87% | 12.56% | Upgrade
|
Free Cash Flow Per Share | 14.37 | -0.12 | 2.83 | 4.75 | 5.12 | Upgrade
|
Cash Interest Paid | 29.53 | 17.9 | 10.07 | 8.57 | 10.59 | Upgrade
|
Cash Income Tax Paid | 228.43 | 151.61 | 109.31 | 103.05 | 97.49 | Upgrade
|
Levered Free Cash Flow | 2,443 | -107.83 | 384.73 | 685.1 | 719.57 | Upgrade
|
Unlevered Free Cash Flow | 2,455 | -98.88 | 388.43 | 687.38 | 724.22 | Upgrade
|
Change in Net Working Capital | -1,804 | 661.22 | 40.69 | -281.29 | -256.97 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.